These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 32898239)

  • 1. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
    Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
    J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
    Chen J; Wang J; Xie F
    Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
    da Fonseca LG; Reig M; Bruix J
    Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
    Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y
    Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
    Zhang CH; Li M; Lin YP; Gao Q
    Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
    Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials.
    Fulgenzi CAM; D'Alessio A; Airoldi C; Scotti L; Demirtas CO; Gennari A; Cortellini A; Pinato DJ
    Eur J Cancer; 2022 Oct; 174():57-67. PubMed ID: 35970037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular therapies and precision medicine for hepatocellular carcinoma.
    Llovet JM; Montal R; Sia D; Finn RS
    Nat Rev Clin Oncol; 2018 Oct; 15(10):599-616. PubMed ID: 30061739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for hepatocellular carcinoma.
    Huang A; Yang XR; Chung WY; Dennison AR; Zhou J
    Signal Transduct Target Ther; 2020 Aug; 5(1):146. PubMed ID: 32782275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
    Personeni N; Pressiani T; Rimassa L
    Future Oncol; 2019 Jul; 15(21):2449-2462. PubMed ID: 31204849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.